Cetera Investment Advisers
PROK icon

Cetera Investment Advisers’s ProKidney PROK Stock Holding History

Cetera Investment Advisers’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,288
Closed -$27.5K – 4932
2025
Q4 		$27.5K Buy
+12,288
New +$32.3K ﹤0.01% 4560

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cetera Investment Advisers's PROK Position: Q1 2026 in Review

Cetera Investment Advisers sold out of ProKidney (PROK) in Q1 2026, closing a stake of 12,288 shares — an estimated $27.5K sold.

Cetera Investment Advisers first reported a position in PROK in Q4 2025 and held it in 1 quarter. The position peaked at $27.5K in Q4 2025. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Cetera Investment Advisers reported no remaining ProKidney position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 12,288 ProKidney shares in Q1 2026, an estimated $27.5K.
  • Cetera Investment Advisers first reported a position in ProKidney in Q4 2025 and held it in 1 quarter.
  • Cetera Investment Advisers's ProKidney position peaked at $27.5K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.